It was observed that the expression of DERL3 is significantly higher in malignant tumors, including clear cell renal carcinoma, bladder cancer, breast cancer, cholangiocarcinoma, hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, thyroid cancer, and endometrial cancer, compared to adjacent normal tissues (Fig 1A). This evidence concerns the gene DERL3 and squamous cell lung carcinoma.